Regulatory PathRegulatory requirements compared

Active substance

Pentazocine

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
TALWINEQ 30MG BASE/MLinjectable · injectionHOSPIRADiscontinued24 Jul 1967
TALWIN 50EQ 50MG BASEtablet · oralSANOFI AVENTIS USDiscontinued3 Feb 1969

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffPentazocine 25mg tablets£27.3928 tablet1 Oct 2026
NHS Drug TariffPentazocine 50mg capsules£28.5028 capsule1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

  • US FDA 7 Oct 2019 TALWIN — safety-related labeling change
    Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for pentazocine →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.